172 related articles for article (PubMed ID: 23497141)
1. Antimalarial screening via large-scale purification of Plasmodium falciparum Ca2+-ATPase 6 and in vitro studies.
David-Bosne S; Florent I; Lund-Winther AM; Hansen JB; Buch-Pedersen M; Machillot P; le Maire M; Jaxel C
FEBS J; 2013 Nov; 280(21):5419-29. PubMed ID: 23497141
[TBL] [Abstract][Full Text] [Related]
2. The Plasmodium falciparum Ca(2+)-ATPase PfATP6: insensitive to artemisinin, but a potential drug target.
Arnou B; Montigny C; Morth JP; Nissen P; Jaxel C; Møller JV; Maire Ml
Biochem Soc Trans; 2011 Jun; 39(3):823-31. PubMed ID: 21599655
[TBL] [Abstract][Full Text] [Related]
3. Purified E255L mutant SERCA1a and purified PfATP6 are sensitive to SERCA-type inhibitors but insensitive to artemisinins.
Cardi D; Pozza A; Arnou B; Marchal E; Clausen JD; Andersen JP; Krishna S; Møller JV; le Maire M; Jaxel C
J Biol Chem; 2010 Aug; 285(34):26406-16. PubMed ID: 20530490
[TBL] [Abstract][Full Text] [Related]
4. Selective Inhibition of Plasmodium falciparum ATPase 6 by Artemisinins and Identification of New Classes of Inhibitors after Expression in Yeast.
Moore CM; Wang J; Lin Q; Ferreira P; Avery MA; Elokely K; Staines HM; Krishna S
Antimicrob Agents Chemother; 2022 May; 66(5):e0207921. PubMed ID: 35465707
[TBL] [Abstract][Full Text] [Related]
5. Structure-based drug design studies of the interactions of ent-kaurane diterpenes derived from Wedelia paludosa with the Plasmodium falciparum sarco/endoplasmic reticulum Ca²⁺-ATPase PfATP6.
Guimarães DS; Fonseca AL; Batista R; Comar Junior M; Oliveira AB; Taranto AG; Varotti Fde P
Mem Inst Oswaldo Cruz; 2015 Apr; 110(2):255-8. PubMed ID: 25946251
[TBL] [Abstract][Full Text] [Related]
6. SERCA plays a crucial role in the toxicity of a betulinic acid derivative with potential antimalarial activity.
Diedrich D; Wildner AC; Silveira TF; Silva GNS; Santos FD; da Silva EF; do Canto VP; Visioli F; Gosmann G; Bergold AM; Zimmer AR; Netz PA; Gnoatto SCB
Chem Biol Interact; 2018 May; 287():70-77. PubMed ID: 29604267
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277).
Uhlemann AC; Wittlin S; Matile H; Bustamante LY; Krishna S
Antimicrob Agents Chemother; 2007 Feb; 51(2):667-72. PubMed ID: 17145800
[TBL] [Abstract][Full Text] [Related]
8. Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6).
Dahlström S; Veiga MI; Ferreira P; Mårtensson A; Kaneko A; Andersson B; Björkman A; Gil JP
Infect Genet Evol; 2008 May; 8(3):340-5. PubMed ID: 18359278
[TBL] [Abstract][Full Text] [Related]
9. Biochemical characterization and chemical inhibition of PfATP4-associated Na
Rosling JEO; Ridgway MC; Summers RL; Kirk K; Lehane AM
J Biol Chem; 2018 Aug; 293(34):13327-13337. PubMed ID: 29986883
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the differences in the cyclopiazonic acid binding mode to mammalian and P. Falciparum Ca2+ pumps: a computational study.
Di Marino D; D'Annessa I; Coletta A; Via A; Tramontano A
Proteins; 2015 Mar; 83(3):564-74. PubMed ID: 25581715
[TBL] [Abstract][Full Text] [Related]
11. Docking studies of structurally diverse antimalarial drugs targeting PfATP6: no correlation between in silico binding affinity and in vitro antimalarial activity.
Garah FB; Stigliani JL; Coslédan F; Meunier B; Robert A
ChemMedChem; 2009 Sep; 4(9):1469-79. PubMed ID: 19645001
[TBL] [Abstract][Full Text] [Related]
12. The binding modes and binding affinities of artemisinin derivatives with Plasmodium falciparum Ca2+-ATPase (PfATP6).
Naik PK; Srivastava M; Bajaj P; Jain S; Dubey A; Ranjan P; Kumar R; Singh H
J Mol Model; 2011 Feb; 17(2):333-57. PubMed ID: 20461426
[TBL] [Abstract][Full Text] [Related]
13. Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins.
Cui L; Wang Z; Jiang H; Parker D; Wang H; Su XZ; Cui L
Antimicrob Agents Chemother; 2012 May; 56(5):2546-52. PubMed ID: 22354307
[TBL] [Abstract][Full Text] [Related]
14. Pumped up: reflections on PfATP6 as the target for artemisinins.
Krishna S; Pulcini S; Moore CM; Teo BH; Staines HM
Trends Pharmacol Sci; 2014 Jan; 35(1):4-11. PubMed ID: 24268763
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
Deniskin R; Frame IJ; Sosa Y; Akabas MH
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
[TBL] [Abstract][Full Text] [Related]
16. Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
Valderramos SG; Scanfeld D; Uhlemann AC; Fidock DA; Krishna S
Antimicrob Agents Chemother; 2010 Sep; 54(9):3842-52. PubMed ID: 20566762
[TBL] [Abstract][Full Text] [Related]
17. Combined receptor-based and ligand-based approach to delineate the mode of binding of guaianolide-endoperoxides to PfATP6.
Helal MA; Avery MA
Bioorg Med Chem Lett; 2012 Sep; 22(17):5410-4. PubMed ID: 22877631
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of artemisinin resistance for malaria PfATP6 L263 mutations and discovering potential antimalarials: An integrated computational approach.
N N; C GP; Chakraborty C; V K; D TK; V B; R S; Lu A; Ge Z; Zhu H
Sci Rep; 2016 Jul; 6():30106. PubMed ID: 27471101
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the Plasmodium falciparum sarcoplasmic/endoplasmic reticulum Ca2+-ATPase gene in samples from Equatorial Guinea before implementation of artemisinin-based combination therapy.
Fernández-Martínez A; Mula P; Cravo P; Charle P; Amor A; Ncogo P; Benito A; Berzosa P
Am J Trop Med Hyg; 2013 Jan; 88(1):43-47. PubMed ID: 23185077
[TBL] [Abstract][Full Text] [Related]
20. Artemisinins target the SERCA of Plasmodium falciparum.
Eckstein-Ludwig U; Webb RJ; Van Goethem ID; East JM; Lee AG; Kimura M; O'Neill PM; Bray PG; Ward SA; Krishna S
Nature; 2003 Aug; 424(6951):957-61. PubMed ID: 12931192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
